Allogeneic hematopoietic cell transplantation for therapy-related myeloid neoplasms arising following treatment for multiple myeloma: a retrospective study on behalf of the Chronic Malignancies Working Party of the EBMT.

Autor: Raj K; Department of Stem Cell Transplantation, University College London Hospitals, London, UK. Kavita.raj@nhs.net., Eikema DJ; EBMT Statistical Unit, Leiden, The Netherlands., Lawless S; Belfast City Hospital, Belfast, Northern Ireland., Koster L; EBMT Leiden Study Unit, Leiden, The Netherlands., Kunadt D; University Hospital Dresden, Dresden, Germany., Kröger N; Department of Stem Cell Transplantation, University Medical Center, Hamburg, Germany., Platzbecker U; Medical Clinic and Policlinic 1, Leipzig, Germany., Stelljes M; University of Muenster, Muenster, Germany., Bethge W; Universitaet Tuebingen, Tuebingen, Germany., Holderried T; Universitaet Bonn, Bonn, Germany., Fanin R; University Hospital and DMED, Division of Haematology and Transplant Center, Udine, Italy., Zeiser R; University Hospital Freiburg, Freiburg, Germany., Kuball J; University Medical Centre, Utrecht, The Netherlands., Leblond V; Universite Paris IV, Hopital la Pitié-Salpêtrière, Paris, France., Nicholson E; Royal Marsden Hospital, London, UK., Passweg J; University Hospital Basel, Basel, Switzerland., Potter V; King's College Hospital, London, UK., Bay JO; CHU ESTAING, Clermont-Ferrand, France., Bazarbachi A; American University of Beirut Medical Center, Beirut, Lebanon., Corral LL; Hematology Department, Hospital Universitario de Salamanca (Spain), IBSAL, CIBERONC, Centro de Investigación del Cáncer-IBMCC (USAL-CSIC), Salamanca, Spain., Gurnari C; Department of Biomedicine and Prevention, University of Rome Tor Vergata, Rome, Italy.; Translational Hematology and Oncology Research Department, Taussig Cancer Center, Cleveland Clinic, Cleveland, OH, USA., Scheid C; University of Cologne, Cologne, Germany., Drozd-Sokolowska J; University Clinical Centre, Medical University of Warsaw, Warsaw, Poland., Morris TC; Belfast City Hospital, Belfast, Northern Ireland., Hayden P; Department of Medicine, Trinity College Dublin, St. James's Hospital, Dublin, Ireland., Yakoub-Agha I; CHU de Lille, Univ Lille, INSERM U1286, Infinite, Lille, France., Robin M; Department of Haematology, Hopital St. Louis, Paris, France., McLornan DP; Department of Stem Cell Transplantation, University College London Hospitals, London, UK.
Jazyk: angličtina
Zdroj: Bone marrow transplantation [Bone Marrow Transplant] 2024 Nov 12. Date of Electronic Publication: 2024 Nov 12.
DOI: 10.1038/s41409-024-02462-5
Abstrakt: Therapy-related myeloid neoplasms (t-MN) are a complication of multiple myeloma (MM) treatment. Our retrospective, EBMT registry study included 157 such patients allografted (allo-HCT) between 2006 and 2018. Most patients (130) had a prior autologous HCT. Fifty-seven (36.4%) were transplanted for t-AML and 100 (63.6%) for t-MDS. Median times from MM and t-MN diagnoses to allo-HCT were 72.6 (interquartile range (IQR), 46.1-102.9) and 6.4 (IQR, 3.9-9.4) months. Fifty-eight (38.4%) t-MN patients were in complete remission (CR) at allo-HCT predominantly conditioned with reduced intensity (70.3%). With a median follow-up of 64.9 (95% CI: 39-76) months, relapse incidence (RI) from MM at 1 and 5 years was 4% (0-10%) and 12% (2-22%), respectively, with few deaths (n = 3) only due to MM disease progression, whereas t-MN RI and non-relapse mortality (NRM) at 1 and 5 years were 35% (95% CI 28-43%) and 45% (95% CI: 36-53%) and 20% (95% CI 13-26%) and 31% (95% CI: 23-39%). Overall survival (OS) and progression-free survival (PFS) estimates at 1 and 5 years were 55% (95% CI: 47-63%) and 27% (95% CI: 19-35%) and 45% (95% CI 36-53%) and 24% (95% CI 16-32%). Older (>65 years) t-MN patients with high-risk cytogenetics do not benefit from allo-HCT.
Competing Interests: Competing interests The authors declare no competing interests.
(© 2024. The Author(s), under exclusive licence to Springer Nature Limited.)
Databáze: MEDLINE
Externí odkaz: